BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36662367)

  • 21. Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Ahn H; Lee HJ; Lee JH; Cho HD; Oh MH; Son JW; Jang SH
    Pathol Res Pract; 2020 Nov; 216(11):153188. PubMed ID: 32919305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
    Shimizu K; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
    Cancer Manag Res; 2017; 9():741-750. PubMed ID: 29238224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
    Jan CI; Tsai WC; Harn HJ; Shyu WC; Liu MC; Lu HM; Chiu SC; Cho DY
    Front Immunol; 2018; 9():727. PubMed ID: 29910795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
    Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma.
    Fu ZM; Zhang DJ; Guo YY; Han S; Guo F; Bai J; Wan YN; Guan GF; Sun KW; Yang N
    Mol Clin Oncol; 2022 Mar; 16(3):59. PubMed ID: 35111324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
    Farrag MS; Abdelwahab K; Farrag NS; Elrefaie WE; Emarah Z
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):16. PubMed ID: 34241710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma.
    Quan H; Yan L; Wang S; Wang S
    Cancer Manag Res; 2019; 11():4335-4345. PubMed ID: 31190998
    [No Abstract]   [Full Text] [Related]  

  • 32. Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters.
    Garg G; Prasad KT; Singh N; Gupta P; Muthu V; Das A; Bal A
    J Pathol Transl Med; 2021 Nov; 55(6):398-405. PubMed ID: 34610234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Relevance of CD4
    Lequerica-Fernández P; Suárez-Canto J; Rodriguez-Santamarta T; Rodrigo JP; Suárez-Sánchez FJ; Blanco-Lorenzo V; Domínguez-Iglesias F; García-Pedrero JM; de Vicente JC
    Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34201050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
    Hongo T; Kuga R; Miyazaki M; Komune N; Nakano T; Yamamoto H; Koike K; Sato K; Kogo R; Nabeshima K; Oda Y; Nakagawa T
    Laryngoscope; 2021 Dec; 131(12):2674-2683. PubMed ID: 34143491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
    Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
    Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor infiltrating T cells influence prognosis in stage I-III non-small cell lung cancer.
    Schulze AB; Evers G; Görlich D; Mohr M; Marra A; Hillejan L; Rehkämper J; Schmidt LH; Heitkötter B
    J Thorac Dis; 2020 May; 12(5):1824-1842. PubMed ID: 32642087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population.
    Ahmadzada T; Cooper WA; Holmes M; Mahar A; Westman H; Gill AJ; Nordman I; Yip PY; Pal A; Zielinski R; Pavlakis N; Nagrial A; Daneshvar D; Brungs D; Karikios D; Aleksova V; Burn J; Asher R; Grau GE; Hosseini-Beheshti E; Reid G; Clarke S; Kao S
    JTO Clin Res Rep; 2020 Nov; 1(4):100075. PubMed ID: 34589956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
    Ou D; Adam J; Garberis I; Blanchard P; Nguyen F; Levy A; Casiraghi O; Gorphe P; Breuskin I; Janot F; Temam S; Scoazec JY; Deutsch E; Tao Y
    Oncoimmunology; 2017; 6(9):e1341030. PubMed ID: 28932643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.